Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Entrada Therapeutics Inc (NASDAQ: TRDA) closed at $10.58 down -0.47% from its previous closing price of $10.63. In other words, the price has decreased by -$0.47 from its previous closing price. On the day, 71114.0 shares were traded. TRDA stock price reached its highest trading level at $10.79 during the session, while it also had its lowest trading level at $10.4.
Ratios:
For a deeper understanding of Entrada Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.08 and its Current Ratio is at 14.08. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In the most recent recommendation for this company, ROTH MKM on December 06, 2024, initiated with a Buy rating and assigned the stock a target price of $29.
On January 05, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $22.
On April 03, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $25.H.C. Wainwright initiated its Buy rating on April 03, 2023, with a $25 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 21 ’25 when WENTWORTH KORY JAMES sold 8,910 shares for $9.98 per share. The transaction valued at 88,932 led to the insider holds 110,026 shares of the business.
BAKER BROS. ADVISORS LP bought 28,867 shares of TRDA for $261,846 on Nov 20 ’25. The 10% Owner now owns 4,691,392 shares after completing the transaction at $9.07 per share. On Nov 21 ’25, another insider, KORY WENTWORTH, who serves as the Officer of the company, bought 8,910 shares for $9.17 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRDA now has a Market Capitalization of 404359456 and an Enterprise Value of 104977272. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.57 while its Price-to-Book (P/B) ratio in mrq is 1.19. Its current Enterprise Value per Revenue stands at 1.706 whereas that against EBITDA is -0.895.
Stock Price History:
The Beta on a monthly basis for TRDA is -0.12, which has changed by -0.4007892 over the last 52 weeks, in comparison to a change of 0.14446163 over the same period for the S&P500. Over the past 52 weeks, TRDA has reached a high of $18.76, while it has fallen to a 52-week low of $4.93. The 50-Day Moving Average of the stock is 20.79%, while the 200-Day Moving Average is calculated to be 39.49%.
Shares Statistics:
For the past three months, TRDA has traded an average of 229.30K shares per day and 202770 over the past ten days. A total of 38.22M shares are outstanding, with a floating share count of 21.74M. Insiders hold about 43.12% of the company’s shares, while institutions hold 48.91% stake in the company. Shares short for TRDA as of 1764288000 were 948628 with a Short Ratio of 3.92, compared to 1761868800 on 893790. Therefore, it implies a Short% of Shares Outstanding of 948628 and a Short% of Float of 4.5600000000000005.
Earnings Estimates
A detailed examination of Entrada Therapeutics Inc (TRDA) is currently in progress, with 4.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.96, with high estimates of -$0.56 and low estimates of -$1.2.
Analysts are recommending an EPS of between -$2.7 and -$3.67 for the fiscal current year, implying an average EPS of -$3.37. EPS for the following year is -$4.0, with 4.0 analysts recommending between -$3.03 and -$4.93.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for TRDA’s current fiscal year. The highest revenue estimate was $60M, while the lowest revenue estimate was $24.12M, resulting in an average revenue estimate of $32.61M. In the same quarter a year ago, actual revenue was $210.78M
